Pfizer Inc. / Capsugel (Pfizer divestiture to KKR)

Pharmaceutical Drug Delivery / Hard Capsule Manufacturing

$750M Capsugel annual revenue (2010, USD)

Disease Overview

Hard two-piece capsules (gelatin and HPMC/vegetarian) are a core oral solid dosage form, used by virtually every major pharma and nutraceutical company. The capsule supply industry is concentrated, capital-intensive, and adjacent to drug-delivery technologies including liquid-filled hard capsules, modified-release formulations, and inhalation dose forms.

Competitive Landscape

At deal time (2011) Capsugel was the global leader in hard capsule supply at ~180B capsules/year and ~$750M revenue, competing principally against ACG Worldwide (India), Suheung (Korea), Qualicaps (Mitsubishi Chemical), and Lonza's capsule subsidiary. The market was structurally attractive — high barriers to entry from regulatory qualification at thousands of pharma customer sites, recurring consumable demand, and pricing power in HPMC/vegetarian variants growing alongside vegetarian and Halal demand. Capsugel's revenue had been roughly flat for two years (down ~4% in 2009, up ~1.3% in 2010) due to a soft dietary supplement market. KKR's investment thesis (industrials team, not healthcare) emphasized engineering quality, emerging-markets expansion in Latin America/China/Middle East, and adjacent drug-delivery platforms (liquid-filled capsules, inhalation, gelatin-free coatings). For Pfizer, the $2.38B sale was part of a portfolio simplification under CEO Ian Read targeting non-core nutritionals/animal health/consumer assets to fund $5B+ buybacks and refocus on innovative pharma R&D — a thesis Bernstein's Tim Anderson called potentially extending to the Established Products unit. Capsugel was sold by KKR to Lonza in 2017 for $5.5B.